Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025)
Powered by 
Analysis
Nu-Med Plus (NUMD) Cash from Operations Growth (1y) (2013 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 21.54% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 48.31% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 64.80% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 13.50% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 14.62% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 124.64% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 0.99% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | -11.16% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | -12.60% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -2,001.56% |
| Dec 31, 2024 | 61.05% |
| Jun 30, 2024 | 89.97% |
| Mar 31, 2024 | 97.77% |
| Dec 31, 2023 | 82.47% |
| Sep 30, 2023 | -3,104.62% |
| Jun 30, 2023 | -809.42% |
| Mar 31, 2023 | -66.14% |
| Dec 31, 2022 | -21.17% |
| Sep 30, 2022 | 101.53% |
| Jun 30, 2022 | 96.18% |
| Mar 31, 2022 | 84.68% |
| Dec 31, 2021 | 71.70% |
| Sep 30, 2021 | 59.42% |
| Jun 30, 2021 | 54.91% |
| Mar 31, 2021 | 16.75% |
| Dec 31, 2020 | 42.85% |
| Sep 30, 2020 | -33.87% |
| Jun 30, 2020 | -22.25% |
| Mar 31, 2020 | 61.41% |